US · PEN · MEDICAL - DEVICES
Penumbra, Inc. (PEN) intrinsic value and stock valuation
$319.12as of 2026-11-21 · Mkt cap 12.73B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Penumbra, Inc. DCF and intrinsic value
InvestorsCraft values PEN with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from PEN’s statements →
Penumbra, Inc. Graham Number
Graham Number: $61.39d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Baxter International Inc. (BAX) $25.39
- Charles River Laboratories International, Inc. (CRL) $314.32
- Align Technology, Inc. (ALGN) $155.17
- DaVita Inc. (DVA) $161.03
- Globus Medical, Inc. (GMED) $66.89
- Henry Schein, Inc. (HSIC) $83.52
- Bio-Rad Laboratories, Inc. (BIO) $358.90
- HealthEquity, Inc. (HQY) $94.75
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.19B | $1.06B | $847.1M | $747.6M |
| Operating income | $189.3M | $86.2M | $73.6M | $6.08M | -$-7.5M |
| Net income | $177.7M | $14M | $91M | -$-2M | $5.28M |
| EPSd | $4.52M | $356.8K | $2.32M | -$-52.85K | $139.4K |
| Operating cash flow | $238.7M | $168.5M | $97.3M | -$-55.66M | $9.5M |
| Capital expenditure | -$-63.73M | -$-21.18M | -$-15.21M | -$-19.3M | -$-21.18M |
| Free cash flow | $174.9M | $147.3M | $82.1M | -$-74.96M | -$-11.68M |
| Total assets | $1.83B | $1.53B | $1.56B | $1.37B | $1.24B |
| Total debt | $219.7M | $223.4M | $234.3M | $235.8M | $173.6M |
| Net debt | $32.8M | -$-101.02M | $66.9M | $165.9M | $114.2M |
| Total equity | $1.43B | $1.15B | $1.18B | $998.9M | $953.9M |
| Cash and short-term investments | $544.8M | $340.1M | $289.2M | $188M | $254.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.19B | $1.06B | $847.1M | $747.6M |
| Cost of revenue | $461.2M | $439.6M | $375.9M | $311.9M | $272.2M |
| Gross profit | $942.4M | $755M | $682.6M | $535.2M | $475.4M |
| Research and development expenses | $89.8M | $94.8M | $84.4M | $79.4M | $104.6M |
| Selling, general and administrative expenses | $663.4M | $574M | $506.5M | $449.7M | $378.3M |
| Other expenses | $0.00 | $0.00 | $18.2M | $0.00 | $0.00 |
| Operating expenses | $753.2M | $668.8M | $609.1M | $529.1M | $482.9M |
| Cost and expenses | $1.21B | $1.11B | $985M | $841.1M | $755.1M |
| Interest income | $16.3M | $13.7M | $6.83M | $1.89M | $2.87M |
| Interest expense | $1.31M | $1.42M | $1.74M | $1.75M | $1.93M |
| Depreciation and amortization | $17.5M | $23.7M | $27.3M | $24.3M | $16.4M |
| Ebitda | $223.9M | $46M | $108.7M | $30M | $7.84M |
| Operating income | $189.3M | $86.2M | $73.6M | $6.08M | -$-7.5M |
| Total other income/expenses, net | $15.9M | -$-65.36M | $6.1M | -$-2.19M | -$-3M |
| Income before tax | $205.1M | $20.9M | $79.7M | $3.89M | -$-10.5M |
| Income tax expense | $27.4M | $6.86M | -$-11.3M | $5.89M | -$-13.12M |
| Net income | $177.7M | $14M | $91M | -$-2M | $5.28M |
| Weighted average shares outstanding | $38.9M | $38.6M | $38.4M | $37.8M | $36.8M |
| Weighted average diluted shares outstanding | $39.3M | $39.3M | $39.2M | $37.8M | $37.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $544.8M | $340.1M | $289.2M | $188M | $254.9M |
| Net receivables | $190M | $167.7M | $201.8M | $203.4M | $133.9M |
| Inventory | $431.6M | $406.7M | $388M | $334M | $263.5M |
| Total current assets | $1.22B | $951.1M | $915.4M | $755.7M | $681.5M |
| Property, plant and equipment, net | $316.4M | $267.8M | $280.5M | $280.4M | $227.1M |
| Goodwill and intangible assets | $173.6M | $173M | $249.4M | $257.8M | $257M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $609.8M | $582.1M | $640.9M | $615.2M | $562.8M |
| Total assets | $1.83B | $1.53B | $1.56B | $1.37B | $1.24B |
| Accounts payable | $34.7M | $31.3M | $27.2M | $26.7M | $13.4M |
| Short-term debt | $16.2M | $14.6M | $13.4M | $12M | $9.98M |
| Deferred revenue | $0.00 | $940K | $6.99M | $9.16M | $0.00 |
| Total current liabilities | $183.1M | $158.3M | $151.1M | $144.9M | $123.2M |
| Long-term debt | $203.5M | $208.8M | $220.9M | $223.8M | $163.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $215.8M | $223.9M | $226.2M | $227.1M | $167.1M |
| Capital lease obligations | $219.7M | $223.4M | $234.3M | $235.8M | $173.6M |
| Total liabilities | $398.9M | $382.3M | $377.4M | $372M | $290.3M |
| Common stock | $40K | $40K | $40K | $40K | $40K |
| Retained earnings | $237.7M | $60M | $134.9M | $43.9M | $45.9M |
| Accumulated other comprehensive income (loss) | $4.35M | -$-5.84M | -$-3.15M | -$-8.12M | -$-2.63M |
| Total equity | $1.43B | $1.15B | $1.18B | $998.9M | $953.9M |
| Total investments | $357.9M | $15.7M | $121.7M | $118.2M | $195.5M |
| Total debt | $219.7M | $223.4M | $234.3M | $235.8M | $173.6M |
| Net debt | $32.8M | -$-101.02M | $66.9M | $165.9M | $114.2M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $177.7M | $14M | $91M | -$-2M | $5.28M |
| Depreciation and amortization | $17.5M | $23.7M | $30.6M | $27.6M | $19.5M |
| Stock-based compensation | $59.2M | $46.2M | $0.00 | $0.00 | $0.00 |
| Change in working capital | -$-42.72M | -$-23.78M | -$-79.08M | -$-121.53M | -$-66.71M |
| Accounts receivable | -$-19.51M | $26.6M | -$-270K | -$-69.86M | -$-21.34M |
| Inventory | -$-26.48M | -$-65.66M | -$-67.71M | -$-74.63M | -$-51.55M |
| Accounts payable | $3.07M | $4.17M | $1.1M | $13.4M | -$-1.56M |
| Net cash provided by operating activities | $238.7M | $168.5M | $97.3M | -$-55.66M | $9.5M |
| Investments in property, plant and equipment | -$-63.73M | -$-21.18M | -$-15.21M | -$-19.3M | -$-21.18M |
| Acquisitions, net | $0.00 | $0.00 | -$-990K | $0.00 | $2.92M |
| Net cash used for investing activities | -$-404.59M | $77.6M | -$-16.08M | $54.8M | -$-21.73M |
| Common stock issued | $31.8M | $17.2M | $20.4M | $21.6M | $18.4M |
| Common stock repurchased | $0.00 | -$-100.39M | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $26.5M | -$-87.01M | $16.2M | $11.6M | $840K |
| Net change in cash | -$-137.51M | $156.9M | $97.6M | $10.5M | -$-10.29M |
| Cash at end of period | $186.9M | $324.4M | $167.5M | $69.9M | $59.4M |
| Operating cash flow | $238.7M | $168.5M | $97.3M | -$-55.66M | $9.5M |
| Capital expenditure | -$-63.73M | -$-21.18M | -$-15.21M | -$-19.3M | -$-21.18M |
| Free cash flow | $174.9M | $147.3M | $82.1M | -$-74.96M | -$-11.68M |
Line items
Line items
Line items
About Penumbra, Inc.
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
- CEO
- Adam Elsesser
- Employees
- 4.7K
- Beta
- 0.70
Included in
Explore
Frequently asked questions
What is the intrinsic value of Penumbra, Inc. (PEN)?
Penumbra, Inc. (PEN) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PEN undervalued?
PEN trades at a price of $319.12 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.